Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies
Completed
Ariad Pharmaceuticals
Phase 1
2008-06-01
The purpose of this study is to determine the maximum tolerated dose or a recommended dose of
oral AP24534 in a defined schedule in patients with refractory or advanced chronic
myelogenous leukemia and other refractory hematologic malignancies.
Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)
Completed
Ariad Pharmaceuticals
Phase 2
2010-09-30
The purpose of this study is to determine the efficacy of ponatinib in patients with chronic
myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or
with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who either are
resistant or intolerant to either dasatinib or nilotinib, or have the
(T)hreonine-315-(I)soleucine (T315I) mutation.
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
Recruiting
Ariad Pharmaceuticals
Phase 2
2011-10-05
This phase II trial studies the side effects and how well combination chemotherapy and
ponatinib hydrochloride work in treating patients with acute lymphoblastic leukemia. Drugs
used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin
hydrochloride, and dexamethasone, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Ponatinib hydrochloride may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth. Giving combination chemotherapy and ponatinib
hydrochloride may be an effective treatment for acute lymphoblastic leukemia.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
